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Signiﬁcant opioid-dependent changes occur during the fourth postnatal week in supraspinal sites (rostro-
ventral medulla [RVM], periaqueductal grey [PAG]) that are involved in the descending control of spinal
excitability via the dorsal horn (DH). Here we report developmentally regulated changes in the
opioidergic signalling within the PAG and DH, which further increase our understanding of pain process-
ing during early life. Microinjection of the l-opioid receptor (MOR) agonist DAMGO (30 ng) into the PAG
of Sprague-Dawley rats increased spinal excitability and lowered mechanical threshold to noxious
stimuli in postnatal day (P)21 rats, but had inhibitory effects in adults and lacked efﬁcacy in P10 pups.
A tonic opioidergic tone within the PAG was revealed in adult rats by intra-PAG microinjection of CTOP
(120 ng, MOR antagonist), which lowered mechanical thresholds and increased spinal reﬂex excitability.
Spinal adminstration of DAMGO inhibited spinal excitability in all ages, yet the magnitude of this was
greater in younger animals than in adults. The expression of MOR and related peptides were also inves-
tigated using TaqMan real-time polymerase chain reaction and immunohistochemistry. We found that
pro-opiomelanocortin peaked at P21 in the ventral PAG, and MOR increased signiﬁcantly in the DH as
the animals aged. Enkephalin mRNA transcripts preceded the increase in enkephalin immunoreactive
ﬁbres in the superﬁcial dorsal horn from P21 onwards. These results illustrate that profound differences
in the endogenous opioidergic signalling system occur throughout postnatal development.
 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.1. Introduction
Supraspinal modulation of spinal pain processing involves
sensitive and precise orchestration of signalling between distinct
anatomical regions, particularly in the periaqueductal grey (PAG)
and nuclei of the rostral ventromedial medulla (RVM) [50]. These
areas form part of a descending pain control axis, with the PAG
integrating pain-related information from the forebrain and relay-
ing appropriate neuromodulatory information to the dorsal horn
(DH) of the spinal cord via pro- and antinociceptive descending
pathways arising in the RVM [5,19,24].
Neonatal responses to noxious stimuli are exaggerated and
often inappropriate [3,17,22,48]. The differences between mature
and neonatal noxious processing are thought to be underpinned
by increased excitation and decreased inhibition at the level of
the DH [28]. Supraspinal control of spinal nociceptive reﬂexes is
slow to develop over the postnatal period [29]. We have previously
shown that although both descending facilitation and inhibition of
spinal excitability can be evoked in adults when the RVM is electri-cally stimulated, in neonatal and juvenile rats, only descending
facilitation can be evoked until at least postnatal day (P)28 [28].
It is known that pharmacological activation of l-opioid
receptors (MORs) within the adult descending pain modulatory
pathway, particularly the PAG and RVM, results in potent analgesia
[5,6,18–20,46,53,57]. Previously, we have shown that microinjec-
tion of the MOR agonist [D-Ala2, N-MePhe4, Gly-ol]enkephalin
(DAMGO) into the RVM of lightly anaesthetised adult rats produces
a dose-dependent decrease in spinal excitability, whereas the same
dose of DAMGO in P21 rats produces reﬂex facilitation [29]. Addi-
tionally, we have demonstrated that blocking the central actions of
endogenous opioid peptides with the potent opioid receptor antag-
onist naloxone between P21 and P28 prevents the normal develop-
ment of descending RVM inhibitory control of spinal nociceptive
reﬂexes [29].
These data indicate that the developmental transition from sup-
raspinally mediated descending facilitation to inhibition of spinal
excitability emanating from the RVM is controlled by opioidergic
activity within the pain modulatory circuit during a critical period
around P21. Furthermore, it suggests that there is a postnatal
reﬁnement in opioidergic neurotransmission within the central
nervous system. Although existing evidence suggests that the
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development may be driven by opioidergic activity within the pain
modulatory circuit, much of this work has been done at the level of
the RVM. A study of opioidergic activity in the PAG over postnatal
development has been neglected.
In this study we demonstrate that signiﬁcant reﬁnement occurs
within speciﬁc components of opioidergic systems of the PAG and
DH, which has profound effects on the inﬂuences of these centres
on pain processing.
2. Methods
2.1. Animals
All animal procedures were licensed by the UK Home Ofﬁce and
performed in accordance with the Animals (Scientiﬁc Procedures)
Act 1986. Our experiments adhered to the guidelines of the Com-
mittee for Research and Ethical Issues of the International Associ-
ation for the Study of Pain. Postnatal day 3, day 14, and adult
(240–260 g) Sprague-Dawley rats were purchased from Charles
River Laboratories (Margate, UK). Pups were housed with their
dams in individually ventilated cages in an in-house animal facil-
ity, weaned when they reached P21, and then group housed in
same-sex cages. Free access to food and water was available
throughout. Experiments were performed on P10, P21, and P40
(adult) rats, and different cohorts of rats were used in electrophys-
iological, immunohistochemical, and TaqMan real-time polymer-
ase chain reaction (RT-PCR) studies. All procedures were
performed during the animals’ light cycle.Fig. 1. Injection sites for saline, DAMGO (30 ng), and CTOP (120 ng) were identiﬁed
histologically post electromyogram recording.2.2. Surgery
PAG microinjection animals were anaesthetised with isoﬂurane
(Baxter; Newbury, Berkshire, UK) and mounted on a stereotaxic
frame (Kopf Instruments, Tujunga, CA, USA). The skull was exposed
and bregma was located. Stereotaxic coordinates for the ventral
PAG (vPAG) were calculated (both adult and P21: left-right [L-R]
0.5 mm; anterior-posterior 7.8 mm; dorsal-ventral [D-V]
6.0 mm; P10: L-R 0.5 mm; anterior-posterior 7.8 mm; DV
4.5 mm) and a 26-gauge 2.5-lL syringe (Hamilton, Reno, NV,
USA) was inserted through a drilled hole in the skull. Drugs were
injected over a 5-minute period, after which the syringe was re-
moved and the wound was closed. Total volume of drug adminis-
tered into the PAG was 1 lL; only one drug was administered
per animal.
Laminectomy animals were anaesthetised and mounted on a
stereotaxic frame. Laminectomy was performed to expose the
L4-5 segments of the spinal cord. The dura mater was carefully
removed, leaving the pia mater intact. This method allows the drug
to be applied directly onto the spinal cord.
Drugs DAMGO (MOR-agonist, 30 ng; Tocris, Abingdon, Oxon,
UK) and CTOP (MOR-antagonist, 100 ng; Tocris) were administered
at doses determined from previously published studies in adult
brainstem [28]. Saline was administered in separate sets of animals
as vehicle control, and it was conﬁrmed that saline either injected
into the PAG or spinally applied had no signiﬁcant effect on spinal
reﬂex excitability. The experimenter was blinded to the drug
administered. Sites of injection in the PAG were conﬁrmed by
examining the lesion tracts after electromyographic (EMG) record-
ings (Fig. 1). The brains were quickly dissected out and kept on dry
ice, and were then coronally sectioned on a freezing microtome
(Leica, Milton Keynes, Bucks, UK). The lesion sites were recorded.
All DAMGO injection sites lay within the vPAG. Data from 2 adult
rats following CTOP microinjection were excluded because the
injection sites fell outside of the vPAG.2.3. Electrophysiological recording
EMG recordings were performed as described previously [24].
Anaesthesia was initially induced at 5% isoﬂurane, which was then
reduced to 3% for surgery. After surgery, isoﬂurane concentration
was further reduced to 1.3% to keep the animals lightly anesthe-
tised. Anaesthesia in P21 and adult rats were maintained with a
surgically implanted endotracheal cannula, whereas in P10 rats it
was maintained with a ﬁtted nose cone. Animals were mounted
onto the stereotaxic frame after tracheotomy. The fur overlying
the biceps femoris muscle was trimmed and a bipolar concentric
needle EMG recording electrode (comprising a modiﬁed 27-gauge
hypodermic needle; Ainsworth, Coventry, UK) was inserted into
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recorded activity is restricted to local muscle activity in small ani-
mals. The EMG electrode was connected to a NeuroLog head-stage
(NL100AK; Digitimer, Welwyn Garden City, UK), signals ampliﬁed
2000 (NL104A), band-pass ﬁltered between 10 and 1000 Hz
(NL125) before being sampled at 2 kHz using LabChart software
via a PowerLab data acquisition unit (AD Instruments Ltd., Oxford,
UK). Isoﬂurane anaesthesia was maintained at 1.3% (small animal
ventilator; Harvard Apparatus, Kent, UK) and rats were left to
equilibrate to anaesthesia for 30 minutes before recording. In these
experiments, spinal reﬂex excitability was determined by the EMG
activity of ﬂexor hind limb muscle evoked by mechanical stimula-
tion of the plantar hind paw using von Frey hairs (vFh). The vFh is a
device that measures mechanical sensitivity/threshold [13]; it is a
series of ﬁne plastic monoﬁlaments of varying diameters that have
progressively stronger bend strengths. The force required to bend
each monoﬁlament is calibrated so that measurements can be
standardised from one individual animal to another.
Responses to 2 sub-threshold vFh (T-1, T-2), and the threshold
hair (T) and a supra-threshold hair (T+1) were recorded and the
same 4 hairs used in all subsequent stimulation conditions for data
analysis. Thresholds were determined as the vFh that produced an
EMG response more than 10% greater than the resting EMG activ-
ity. Each hair was then applied 3 times, and the mean reading for
each of the 3 presentations recorded. Previous studies have shown
that mechanical withdrawal thresholds are signiﬁcantly lower in
P10 and P21 than in adult animals [21], therefore, different hairs
were used in each age group.
A stimulus-response curve of EMG magnitude vs mechanical
stimulus intensity was plotted and the area under the curve was
calculated to provide an integrated measure of spinal reﬂex excit-
ability. The value obtained was considered as the predrug response
of the animal. Subsequent responses following pharmacological
manipulations were normalised to this because of variations in
background (nonevoked) EMG activity. vFh stimulations were
carried out for the next 30 minutes at 10-minute intervals. Predrug
responses were normalised as 100%, therefore, an increase (>100%)
indicates a facilitation, whereas a decrease (<100%) indicates an
inhibition of spinal reﬂex excitability.
In this study,mechanical threshold postdrug administrationwas
presented as a percentage change of the predrug threshold
([mechanical threshold postdrug administration (grams)  pre-
drug threshold (grams)]/predrug threshold  100%). Therefore, a po-
sitive value would indicate an inhibition of nociceptive responses
(analgesia), whereas a negative value would indicate facilitation.
2.4. Tissue collection for TaqMan RT-PCR
P10, P21, and adult rats were killed by an overdose of pentobar-
bital (2.5 mL per animal, intraperitoneally) and brains and spinal
cords were quickly dissected out on ice. Tissue from the PAG and
lumbar (L3-L5) spinal cord were isolated, with the PAG and spinal
cord further subdivided into dorsal and ventral parts with a scalpel
blade. Samples were put into separate cryovials for ﬂash freezing in
liquid nitrogen and stored at 80C. Three to seven animals were
included in each age group.
2.5. Quantitative real-time PCR
TaqMan quantitative RT-PCR was performed using the StepOne-
Plus real-time PCR system (Applied Biosystems, Forster City, CA,
USA). Primers and probes for glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH; National Center for Biotechnology Information
[NCBI] reference sequence NM_017008.3), pro-opiomelanocortin
(POMC; NCBI reference sequence NM_139326.2), enkephalin
(ENK; NCBI reference NM_017139.1) and MOR 1A (MOR-1A; NCBIreference sequence NM_001038597.2) were designed on Primer
Express 3 (Applied Biosystems). The POMC and GAPDH probes
were labelled at the 50 end with 6-carboxyﬂuorescein and at the
30 end with tetramethylrhodamine. The MOR-1A and ENK probes
were labelled at the 50 end with 6-carboxyﬂuorescein and the 30
end with dihydrocyclopyrroloindole tripeptide minor groove bin-
der. The probes were speciﬁcally designed to span across an in-
tron-exon boundary in order to avoid potential ampliﬁcation of
genomic DNA in the analysed samples. Each sample was loaded
onto 96-well plates and run in triplicate. Expression of target genes
(POMC, MOR-1A, ENK) were normalised to GAPDH, and transcript
regulation was determined using the relative standard curve meth-
od per manufacturer’s instructions.
2.6. Perfusion
Rats that were included in immunohistochemical investigations
were perfused transcardially with 150 mL of saline and then
200 mL of 4% paraformaldehyde (Sigma, Dorset, UK) in 0.1 M phos-
phate-buffered saline (PBS). Immediately after ﬁxation, brains
were removed and postﬁxed in 4% paraformaldehyde at 4 C over-
night. Tissue was stored in 30% sucrose solution in 0.1 M PBS con-
taining 0.01% azide (Sigma) for at least 1 day for cryoprotection
before sectioning.
2.7. Immunohistochemistry
The PAG and lumbar spinal cord were sectioned using a freezing
microtome (Leica, model number SM2010R) set at a nominal thick-
ness of 40 lm. The free-ﬂoating sections were washed in 0.1 M PBS
3 times. The sections were blocked in 3% goat serum, 0.3% triton
solution in 0.1 M PBS for 1 hour at room temperature immediately
before they were incubated with primary antibodies to reduce
nonspeciﬁc background staining. All antibody solutions were made
up in Tris-buffered saline. Sections were incubated overnight with
constant agitation at room temperature. The primary antibodies
used were rabbit anti-POMC (1:100; Phoenix Pharmaceuticals
Inc., Burlingame, CA, USA), rabbit anti-MOR (Neuromics, Edina,
MN, USA; 1:1000 with tyramide signal ampliﬁcation protocol),
and mouse anti-ENK (1:100; Fitzgerald, Acton, MA, USA) overnight
at room temperature. For direct staining, sections were washed in
0.1 M PBS 5 times at 10-minute intervals and incubated with ﬂuo-
rescent secondary antibodies for 2 hours at room temperature.
Goat antirabbit Alexa-488 (Invitrogen, Paisley, UK) was used to
detect POMC immunoreactivity, and goat antimouse Alexa-568
(Invitrogen, UK) to detect ENK immunoreactivity.
Following incubation of rabbit anti-MOR antibody, signals were
ampliﬁed using a tyramide ampliﬁcation protocol. Sections were
ﬁrst incubated with appropriate secondary biotinylated antibodies
(1:400, 1.5 hours) followed by avidin-biotin complex (ABC elite;
1:250 Vectastain A plus 1:250 Vectastain B; Vector Laboratories,
Peterborough, UK) for 30 minutes followed by a signal ampliﬁca-
tion step with biotinylated tyramide solution (1:75, 7 minutes;
Perkin Elmer, Buckinghamshire, UK). Sections were then incubated
with ﬂuorescein isothiocyanate avidin (1:600, Vector Laboratories)
for a further 2 hours.
Finally, after secondary antibody or tyramide signal ampliﬁca-
tion incubation, sections were washed 5 times at 10-minute inter-
vals with 0.1 M PBS (ﬁrst 4 washes, the last wash with ddH2O).
They were then mounted on gelatine-coated slides and covers-
lipped using Fluoromount (Sigma).2.8. Microscopy and quantiﬁcation
Immunoﬂuorescent sections were observed with a Leica IRE2
ﬂuorescence microscope ﬁtted with Hamamatsu Orca-ER
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(Perkin Elmer, UK). Image J 1.29 (National Institutes of Health,
Bethesda, MD, USA) was used to adjust brightness and contrast
of the images postacquisition. Three to six brains per age were pro-
cessed in this way. For each anatomical region (vPAG and DH), the
area of interest was outlined and selected by using the region of
interest function of the Volocity software and the motorised stage
(Prior Scientiﬁc, Cambridge, UK). Forty-times magniﬁcation images
were taken for each section. Same exposure time of image acquisi-
tion was used for each section, staining for the different antibodies
from the different animals to ensure consistent brightness in
images. The 40 images (raw tiles) were then stitched together
at 40% overlapping to form a composite image of the area of inter-
est; the raw tiles were saved into a separate folder for
quantiﬁcation.
Systematic random sampling and unbiased stereological meth-
ods were used for quantiﬁcation as adopted from previously pub-
lished studies [26,37]. Six raw tiles were chosen from area of
interest for quantiﬁcation, the ﬁrst raw tile was always included,
and 5 other raw tiles were selected at regular intervals according
to the number of tiles collected for the section. Number of cells
and staining intensity were accounted for as follows. A counting
frame was superimposed onto the raw tile, the right and upper
boundary of the tile were ‘‘forbidden lines,’’ the left and bottom
boundary were ‘‘acceptance line.’’ Number of cells was counted
only if they either lay entirely within the counting frame or cross
an acceptance line without also crossing a forbidden line [31,37].
The staining intensity was estimated with Image J. The data
obtained were added together to form an estimate of the number
of POMC-, MOR-, and ENK-positive cells or ﬁbres. This process
was repeated for each animal.
For the purpose of presentation, images were also captured on a
Leica DMIRE ﬂuorescent microscope with a TCS SP1 confocal head
and a 40 oil immersion objective.
2.9. Data analysis and statistics
All individual data points were represented as mean ± SEM.
EMG data were normally distributed. Comparisons were made
between the baseline values and those obtained following
intra-PAG microinjections within each individual animal using
repeated-measures one-way analysis of variance (ANOVA) with
Bonferroni posttests. Statistical comparisons between the age
groups and drugs were made using 2-way ANOVA with Bonferroni
posttests. Statistical comparison between the age groups for the
expression of various endogenous opioid targets in TaqMan
RT-PCR and immunohistochemical experiments were made by
one-way ANOVA with Bonferroni posttests.
3. Results
3.1. Baseline EMG activity does not change signiﬁcantly between ages
Baseline EMG activity in P10, P21, and adult rats were not sig-
niﬁcantly different (see Figs. 2A, B and 3A, B).
3.2. Spinal l-opioid receptor activation causes a decrease in nociceptive
responses in all ages
As neonatal animals have signiﬁcantly lower mechanical
thresholds than older animals, different ranges of stimuli were
used in the different age groups. Fig. 2A and B shows typical raw
EMG traces evoked by mechanical stimulation of the plantar hind
paw using vFh in each age group before and after spinal adminis-
tration of DAMGO (Fig. 2A) and CTOP (Fig. 2B). Direct applicationof DAMGO (30 ng) onto the L4-5 spinal cord of lightly anaesthe-
tised rats (n for P10 = 4, P21 = 8, adult = 5) produced a reduction
in spinal reﬂex excitability [2-way ANOVA, drug  age interaction:
F(4, 135) = 4.43, P < 0.01; Fig. 2C]. Signiﬁcant reductions in spinal
excitability were observed at all age groups between saline- and
DAMGO-treated animals (P < 0.0001 for P10 and adults and
P < 0.001 for P21 rats). The degree of inhibition observed was sig-
niﬁcantly greater in the P10 rats compared to adults
(P10 = 3.97 ± 0.97% vs adult = 50.76 ± 8.79%, P < 0.01), illustrating
the greater potency of opioidergic ligands in younger animals.
The MOR antagonist CTOP (120 ng) applied spinally had no effect
on reﬂex excitability in all ages (n for P10 = 4, P21 = 7, adult = 7)
when compared to saline or to predrug responses [P10:
F(3, 9) = 3.82, P = 0.51; P21: F(3, 18) = 0.76, P = 0.53; adult:
F(3, 18) = 1.39, P = 0.28; Fig. 2C].
Changes in reﬂex excitability were also accompanied by parallel
changes in mechanical threshold (Fig. 2D). Mechanical thresholds
signiﬁcantly increased after DAMGO was applied spinally [2-way
ANOVA, drug  age interaction: F(4, 135) = 5.70, P < 0.01;
Fig. 2D]. Comparisons between the different drug treatment groups
showed that DAMGO signiﬁcantly increased thresholds compared
to saline in P10 and P21 rats (P < 0.0001), but not in adults. As with
changes in EMG excitability, comparisons between the age groups
showed that DAMGO-mediated increases in threshold were larger
in P10 and P21 rats when compared to DAMGO-treated adults
(both P < 0.01; Fig. 2D). Spinal application of CTOP had no effect
on mechanical threshold at any age when compared to saline-trea-
ted groups or predrug responses, but in P10 and P21 animals, post-
CTOP responses were signiﬁcantly different from post-DAMGO re-
sponses (P < 0.0001; Fig. 2D).3.3. Intra-PAG DAMGO facilitates nociceptive responses in immature
rats but inhibits them in adults
Previously, we have shown that DAMGO applied to the RVM
is pronociceptive in P21 rats whilst being analgesic in adults
[29]. The PAG is the major source of afferent input to the RVM
and we were therefore interested in investigating whether this
excitatory effect of DAMGO was also present in the immature
PAG. Fig. 3A and B shows typical raw EMG traces evoked by
mechanical stimulation of the plantar hind paw using vFh in
each age group before and after intra-PAG microinjection of
DAMGO and CTOP, respectively. Administration of DAMGO
(30 ng; n for P10 = 4, P21 = 6, adult = 7) and CTOP (120 ng; n
for P10 = 4, P21 = 7, adult = 5) produced differential responses
in the different age groups with respect to reﬂex excitability
[2-way ANOVA, drug  age interaction: F(4, 126) = 17.14,
P < 0.0001; Fig. 3C] and mechanical thresholds [2-way ANOVA,
drug  age interaction: F(4, 126) = 84.89, P < 0.0001; Fig. 3D]. In
P10 rats, neither DAMGO nor CTOP had any effect on spinal
excitability when compared to saline-treated animals or predrug
responses [DAMGO: F(3, 9) = 3.32, P = 0.07; CTOP: F(3, 9) = 1.52,
P = 0.28]. DAMGO, however, signiﬁcantly facilitated spinal excit-
ability in P21 rats (P < 0.001 vs saline; P < 0.05 vs predrug re-
sponses; Fig. 3C) and this was accompanied by a signiﬁcant
reduction in mechanical thresholds when compared to saline-
treated rats (P < 0.0001 vs saline; Fig. 3D). The comparisons of
the effects of intra-PAG DAMGO between P21 and both P10
and adult rats showed that DAMGO is pronociceptive in P21 rats
only. Spinal reﬂex excitability after DAMGO injection into the
PAG in P21 was signiﬁcantly higher when compared to P10
and adult rats (P < 0.001 vs P10; P < 0.0001 vs adults; Fig. 3C).
Mechanical threshold was also signiﬁcantly lower in P21 when
compared to adults (P < 0.0001; Fig. 3D).
Fig. 2. Spinal l-opioid receptor (MOR) activation reduces nociceptive responses in all ages. (A) Typical electromyographic (EMG) traces in postnatal day (P)10, P21, and adult
rats during baseline (without any stimulation), predrug (a typical threshold response before application of drug) and postdrug (A: DAMGO 30 ng; B: CTOP 120 ng) periods.
The application of MOR opioid agonist DAMGO onto the spinal cord produced antinociceptive responses in all ages tested. Spinal reﬂex excitability (C) was decreased when
compared to age-matched saline and predrug responses in all ages, both saline and CTOP had no signiﬁcant effect. Mechanical threshold (D) was increased when DAMGO was
administered in P10 and P21 rats. ++, ++++P < 0.01, 0.0001 compared to predrug responses. ⁄⁄⁄, ⁄⁄⁄⁄P < 0.001, 0.0001 compared to other age-matched drug groups. ##P < 0.01
compared to other drug-matched age groups.
172 C.H.T. Kwok et al. / PAIN

155 (2014) 168–1783.4. Tonic opioidergic tone in the PAG of adults is absent in younger
rats
CTOP (120 ng) signiﬁcantly increased spinal excitability in adult
rats (P < 0.0001 vs saline and DAMGO; Fig. 3C). In P21 rats, reﬂex
excitability was increased compared to predrug responses only
(P < 0.05; Fig. 3C), and this effect was small (100% vs
113.2 ± 6.85%). No effect was observed in P10 when compared to
saline-treated age-matched controls or predrug responses. Theincrease in adult spinal excitability was accompanied by a signiﬁ-
cant reduction in mechanical threshold when compared to saline
(P < 0.05) or changes in threshold in P10 or P21 rats (both
P < 0.01; Fig. 3D). These data show that MOR-mediated signalling
in the PAG produces differential responses over postnatal develop-
ment. At P21, but not P10, DAMGO in the PAG is pronociceptive,
whereas it is inhibitory in adult rats. Furthermore, antagonising
MOR has signiﬁcant effects in adult rats, indicating the presence
of a tonic opioidergic tone within the mature PAG.
Fig. 3. Periaqueductal grey (PAG) l-opioid receptor (MOR) activation produces differential age-speciﬁc effects in nociceptive responses. (A) Typical electromyographic (EMG)
traces in postnatal day (P)10, P21, and adult rats during baseline (without any stimulation), predrug (a typical threshold response before application of drug) and postdrug (A:
DAMGO 30 ng; B: CTOP 120 ng) periods. The microinjection of DAMGO and CTOP into the PAG produced differential nociceptive responses between the ages. Spinal reﬂex
excitability (C) post-DAMGO was unchanged in P10 rats, but was facilitated in P21 and inhibited in adults when compared to predrug responses and to age-matched saline
groups. CTOP elevated spinal reﬂex excitability in P21 rats when compared to predrug responses, and in adults when compared to age-matched saline groups. Mechanical
threshold (D) was unchanged in P10 rats, but was decreased in P21 rats when compared to age-matched saline groups and increased in adults when compared to both
predrug responses and age-matched saline groups. CTOP signiﬁcantly decreased mechanical threshold in adult rats when compared to predrug and age-matched saline
responses. +, ++P < 0.05, 0.01 compared to predrug responses. ⁄, ⁄⁄⁄, ⁄⁄⁄⁄P < 0.05, 0.001, 0.0001 compared to age-matched drug groups. ##, ###, ####P < 0.01, 0.001, 0.0001
compared to drug-matched age groups.
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receptors undergo signiﬁcant postnatal alterations
The switch from net facilitatory to tonic inhibitory output in
opioidergic signalling within the PAG over postnatal development
may reﬂect underlying changes in the expression of MOR and opio-
idergic peptides. To test this hypothesis, TaqMan RT-PCR was em-
ployed to assess whether expression of endogenous opioidergictargets are changed during the postnatal period. TaqMan RT-PCR
for POMC (pro-opiomelanocortin, precursor peptide of b-endor-
phin), ENK, and MOR (MOR-1A) was performed in the PAG and
spinal cord of P10, P21, and adult rats.
Here we report signiﬁcant changes in POMCmRNA copies in the
vPAG between the 3 ages [one-way ANOVA, F(2, 16) = 3.65,
P 6 0.05; Fig. 4A]. In particular, posttests revealed there were
signiﬁcantly more POMC mRNA copies in P21 vPAG when
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mRNA copy numbers in the dorsal PAG (dPAG) throughout postna-
tal development (data not shown). Copy numbers of mRNA for ENK
or MOR1A within the vPAG or the dPAG (data not shown) were not
signiﬁcantly different between the ages.
Transcription of ENK mRNA in the DH undergoes signiﬁcant
postnatal reﬁnement [one-way ANOVA, F(2, 7) = 8.04, P < 0.05;
Fig. 4B]. We found highest ENK mRNA copies in P10, and lowest
at P21 (P < 0.05 vs P10). There were no signiﬁcant age-related
changes in ENK mRNA copy number in the ventral horn (data not
shown), there were also no changes in MOR mRNA copy numbers
in either the DH or the ventral horn (data not shown).
3.6. Age-dependent changes in the expression of POMC, ENK, and
l-opioid receptors within the PAG
Immunoreactivity for POMC was found in both the dPAG and
the vPAG in all ages tested. Since there were no signiﬁcant
differences in POMC, ENK, and MOR immunoreactivity in the dPAG
between the ages, these data are not shown. At P10, ﬁbre staining
of POMC can be observed in the vPAG, which became more re-
stricted to the ventral side of the aqueduct at later ages. Staining
intensity within the vPAG was statistically higher the older ani-
mals became [one-way ANOVA, F(2, 9) = 23.91, P < 0.001;
Fig. 5B]. Posttests revealed that POMC immunoreactivity was the
lowest in P10 (P10 vs adult and P21 both P < 0.001; Fig. 5B). Both
ENK immunoreactive ﬁbres and cells (indicated by white arrows;Fig. 4. Transcription of genes encoding endogenous opioid peptides and receptors
during postnatal development. (A) mRNA transcript numbers of POMC (pro-
opiomelanocortin), ENK (enkephalin), and MOR (l-opioid receptors) in the vPAG
(ventral periaqueductal grey). There were no changes in ENK and MOR transcription
levels between the ages. There was a signiﬁcant increase in POMC mRNA transcript
numbers at postnatal day (P)21; in particular, there were more POMC in P21 when
compared to adult (⁄P < 0.05). (B) mRNA transcript numbers of POMC, ENK, and
MOR in the DH (spinal cord dorsal horn). There were no changes detected with
either POMC or MOR. There was a signiﬁcant increase in ENK mRNA transcript
numbers as the animals aged, and it was highest at P10 (⁄vs P21). Data presented in
both A and B were expressed as mean ± SEM of the ratio of transcript number of
target gene divided by transcript number of glyceraldehyde 3-phosphate dehydro-
genase (GAPDH; reference gene).Fig. 5C) were found. Since only ﬁbre staining could be found in
the majority of sections investigated, staining intensity was mea-
sured, but no statistically signiﬁcant changes in staining intensity
were detected (Fig. 5D). MOR staining was observed in all the re-
gions tested at all ages, but particularly in the more ventral parts
of the vPAG (Fig. 5E). Since MOR immunoreactivity was found in
cells, we quantiﬁed our data here by cell counting. There are no sig-
niﬁcant changes in the number of MOR-positive staining between
the ages in the vPAG (Fig. 5F).
3.7. Age-dependent changes in the expression of POMC, ENK, and
l-opioid receptors within the DH
In the DH, POMC-positive cell staining was seen in both super-
ﬁcial and deeper laminae of the DH. As the animals aged, staining
became more localised to the superﬁcial lamina, and ﬁbre staining
could be seen in lamina I of adult rats (indicated by white arrows,
Fig. 6A). Overall, the intensity of staining decreased as the animals
aged [F(2, 9) = 9.16, P < 0.01]. Posttests revealed that POMC immu-
noreactivity was the highest in P10 (P10 vs P21, P < 0.05; P10 vs
adult, P < 0.01; Fig. 6B). ENK immunoreactivity in the DH signiﬁ-
cantly increased as the animals aged [F(2, 13) = 8.61, P < 0.01].
Posttests revealed that ENK immunoreactivity was the highest in
adult rats (P10 vs adult and P21 vs adult, both P < 0.05; Fig. 6D).
Most ENK ﬁbre staining in the DH was observed in the superﬁcial
laminae (lamina I and II) in all of the ages, but immunoreactivity
intensiﬁed as the rats reached maturity. Signiﬁcantly more MOR
immunoreactive cells were found in the DH of older rats when
compared to P10 animals [F(2, 15) = 9.64, P < 0.01]. Posttests re-
vealed that there was more MOR immunoreactivity in the adult
and P21 when compared to P10 in the DH (P < 0.05 and P < 0.01,
respectively; Fig. 6E).4. Discussion
Supraspinal nociceptive processing in neonatal animals and hu-
mans is signiﬁcantly different from adults [21,35,40]. As the sys-
tem matures, activation of supraspinal nociceptive pathways
become increasingly inhibitory, thus, a ﬁne-tuned balance of facil-
itatory and inhibitory control of spinal excitability is formed
[21,28,29]. Little is known about the inﬂuences of immature supra-
spinal pathways on spinal nociceptive processing or the factors
that drive the development of supraspinal nociceptive pathways
throughout normal maturation [38]. One reason for this gap in
our knowledge is that mechanisms underlying the switch from
facilitation to inhibition during development are likely to be mul-
tifaceted [45].
Here we have focused on opioidergic pathways within the PAG
and spinal cord. POMC is the precursor molecule for b-endorphin,
which is a major bioactive opioid peptide. Both ENK and MOR
are known to play a role in supraspinal pain processing and are ex-
pressed and functional within the descending pain modulation cir-
cuit [6,14,39,41,47]. Although not an exhaustive list of opioid
receptors and related peptides, we have chosen MORs because they
are known to be central to the function of the PAG, are abundantly
expressed within the region [27,44], and play a signiﬁcant role in
pain modulation [9,25,56].
4.1. MOR activation in the PAG differentially modulates spinal excitability
in an age-dependent manner
The PAG and RVM represent the major supraspinal centres con-
trolling spinal excitability [6,19,20]. Here we have demonstrated
that the endogenous opioidergic system within the PAG signiﬁ-
cantly changes in the postnatal period of the rat. Pharmacological
Fig. 5. Immunohistochemical expression of opioid peptides and receptors in the vPAG (ventral periaqueductal grey) during postnatal development (A) Epiﬂuorescent images
showing POMC (pro-opiomelanocortin) immunoreactive ﬁbre staining of the ventral PAG (vPAG) in postnatal day (P)10, P21, and adult animals. (B) A histogram showing
quantiﬁed staining intensity of POMC in the vPAG of the 3 ages (measured by intensity function ImageJ), which increased dramatically as the animals aged (⁄⁄⁄P < 0.001 vs P21
and adult). (C) Enkephalin immunoreactivity in the vPAG of P10, P21, and adult animals. (D) Staining intensity of enkephalin-positive ﬁbres did not vary between the ages. (E)
MOR (l-opioid receptor) staining in the vPAG, the location was more ventral when compared to POMC and enkephalin images because that was where we found most MOR
immunoreactive cells. (F) Cell counts for MOR positive cells in the vPAG, no changes were detected between the ages. All images shown in A, C, and E were imaged with a 40
objective with a confocal head.
C.H.T. Kwok et al. / PAIN

155 (2014) 168–178 175activation of the MOR via DAMGO (30 ng/rat) in the PAG is prono-
ciceptive in P21 rats, antinociceptive in adults, and lacks an effect
in P10s. We have previously observed DAMGO-mediated spinal
facilitation in the RVM [29]. The PAG exerts descending control
to the spinal cord DH indirectly via the RVM [20], and the concur-
rent reversal of the predicted effects of DAMGO within both the
PAG and RVM indicates that these structures undergo comparable
postnatal modiﬁcations. The cellular mechanisms responsible for
the DAMGO-mediated facilitation of spinal excitability are cur-
rently unknown and are the focus of on-going experimental re-
search. There are several studies that report facilitatory effects of
opioid agonists [15,29], with the MOR particularly being shown
to be able to signal via Gs rather than the typical Gi-protein second
messenger systems [51]. The underlying mechanisms by which
this biased signalling occurs are currently unknown, but have sig-
niﬁcant implications for the study of opioids in neurodevelopment
and for the utility of these drugs as analgesic agents.
There are numerous reports of opiate-mediated inhibition of
cellular activity and integrated pain responses within the adult
PAG [32,49,52], but few investigating the activity of opioid pep-
tides in younger rats. Recently, a study has demonstrated potent
opioid-mediated antinociception elicited from the PAG, RVM, or
dorsolateral pons in P3, P10, and P14 rats, which contradicts data
presented here [4]. However, the differences between our studies
in terms of assay of pain behaviour, modality of stimulus, and dose
of DAMGO administered may explain some of these contradictions.
Our study is performed in lightly anaesthetised rats, which areroutinely used in studies investigating pain control in neonates
[8,21,35,55]. This experimental preparation removes confounding
factors such as handling stress, novel testing environment, and
perhaps most importantly, the effects of a protracted period of
maternal separation, which are known to signiﬁcantly affect pain
responding in neonates via an opioid-dependent pathway [33,34].
Our electrophysiological studies (MOR-mediated antagonism
by CTOP) showed that within the PAG, tonic opioidergic control
of neurotransmission exists in adult rats. Although a small increase
in spinal reﬂex excitability was seen in P21 rats when CTOP was in-
jected into the PAG, there were no signiﬁcant differences between
post-CTOP and postsaline responses in both reﬂex excitability and
mechanical threshold. On the other hand, in adult rats, CTOP in-
creased spinal nociceptive reﬂex excitability, and mechanical
thresholds (P40 on Fig. 3D) were also signiﬁcantly decreased in
adult rats after the drug was injected into the PAG. These results
suggest that supraspinal MORs are tonically active in the healthy,
mature pain-modulation circuit. It is also evident that, in our ana-
tomical studies, the expression of POMC in the PAG increased as
the animals aged (Fig. 5A, B). Together, these physiological and
anatomical data suggest that opioid-related activity in the mature
PAG is higher when compared to neonates. Neonatal injury is
known to induce changes in the functioning of pain modulation
in later life [30,54,55] and increase opioidergic tone from the
PAG [36]. Neonatal pain experience therefore shapes pain respond-
ing in adulthood, and supraspinal opioidergic systems are central
to this process.
Fig. 6. Immunohistochemical expression of opioid peptides and receptors in the DH (spinal cord dorsal horn) during postnatal development. (A) POMC (pro-
opiomelanocortin) immunoreactivity in the dorsal horn in postnatal day (P)10, P21, and adult rats. White arrows depict where cell staining was found. Interestingly, ﬁbre
staining was also observed in the superﬁcial dorsal horn (lamina I) of adult rats, but not in the younger ages. (B) Since both cell and ﬁbre staining were observed, staining
intensity was used to quantify the immunoreactivity of POMC in the DH. Quantiﬁed staining intensity for POMC in the DH signiﬁcantly decreased as the animals aged, with
highest immunoreactivity found at P10 (⁄P < 0.05 vs P21; ⁄⁄P < 0.01 vs adult). (C) Enkephalin immunoreactivity in the DH was restricted to the superﬁcial laminae and only
ﬁbre staining was observed. (D) Quantiﬁed staining intensity for enkephalin illustrate an age-dependent increase in immunoreactivity, which was highest at adult (⁄P < 0.05
vs P21 and P10). (E) MOR (l-opioid receptor) immunoreactivity in the DH, cell staining was found throughout the superﬁcial and deeper laminae in all ages. (F) Cell count of
MOR staining in the DH, which showed a signiﬁcant increase as the animals aged (⁄⁄P < 0.01 vs P21; ⁄P < 0.05 vs adult).
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adult rats
Application of DAMGO to the spinal cord produced profound
analgesia in all ages tested. This effect of DAMGO was signiﬁcantly
greater in P10 pups when compared to adults (Fig. 2). These ﬁnd-
ings suggest that opioid-mediated signalling in the spinal cord is
stronger in the younger rats when compared to adults, which is
in agreement with ﬁndings from previously published studies
[10–12,42,43]. Opioid receptors and related peptides are present
on both primary sensory afferents and intrinsic neurons within
the adult DH [16]. These are often co-localised with calcitonin-
gene related peptide [1] and substance P [7]. In neonatal animals,
MOR binding sites in the spinal cord are equally concentrated in
the superﬁcial and deeper laminae, and as animals age, their
expression becomes reﬁned to the superﬁcial DH [2]. Calcium
imaging in cultured dorsal root ganglia has shown that neonatal
sensory neurones of all ﬁbre types (C, Ad, and Ab) are sensitive to
morphine, whereas only small-calibre ﬁbres are sensitive in adult
dorsal root ganglia [42]. It is perhaps this functional reorganisation
of MORs that leads to the differences in sensitivity and selectivity
of opioidergic actions in the spinal cord between neonatal and
adult rats.
Our data failed to show a signiﬁcant increase in mechanical
threshold following DAMGO administration to the adult spinal
cord. Baseline thresholds in adult rats are signiﬁcantly higher than
in either P21 or P10 rats [21], and a ceiling effect was observed
whereby thresholds increased beyond the range of mechanicalstimuli available to us. It should be noted that spinal excitability
in adults was signiﬁcantly decreased.
4.3. Alterations in the transcription and expression pattern of opioid
peptides and receptors
The switch in PAG MOR-mediated activity may also reﬂect the
developmental regulation of the underlying cellular expression
and distribution of opioid receptors within the circuit, and/or epi-
genetic control of genes that code for downstream signalling pro-
teins [45]. It has been suggested that sufﬁcient levels of
endogenous opioids are needed for the maturation of pain path-
ways during a critical period between P21 and P28 [29]. The
endogenous opioid system has also previously been implicated to
play a role in the regulation of cell growth and differentiation in
the developing brain [58]. One explanation for the increase in
expression of opioidergic target may be that MOR-mediated activ-
ity is necessary for synaptogenesis within the descending pain
modulatory circuit. The majority of previous studies investigating
the ontogeny of the opioid peptides have relied upon SYBR Green
[29] or radioimmunoassay [47] assays, but both have lower spatial
resolution compared to immunohistochemistry, and lack the sensi-
tivity of TaqMan RT-PCR used in this study [23].
Both immunoﬂuorescence and TaqMan RT-PCR illustrated that
expression level of POMC was highest at P21, which agrees with
our previously described opioid-dependent critical period in the
maturation of top-down pain control [29]. The expression of
MOR shows a similar trend: increasing numbers of MOR immuno-
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highest level of expression was found at P21. The signiﬁcant
increase in POMC immunoreactivity around P21 coincides with
the critical period of the development of supraspinal pain path-
ways [29], whereby the output of activating these pathways
changes from being primarily facilitatory to increasingly
inhibitory.
Immunoﬂuorescence data show that ENK signiﬁcantly in-
creased in the DH as the animals aged, but the TaqMan RT-PCR
data show that mRNA copy numbers were the highest in P10 DH.
Although one may expect the increase in mRNA expression to
precede protein translation, this is an unlikely explanation for
these discrepancies. Instead it should be remembered that tissue
taken for TaqMan will not include the cell bodies of the cells whose
ENK-positive ﬁbres are so prominent in the adult DH. The origin of
these ﬁbres is currently unknown, yet it is likely that these ﬁbres
are primary afferent nerve terminals rather than terminals of
descending ﬁbres.
These results altogether show that the endogenous opioid
system undergoes crucial reﬁnements in the descending pain mod-
ulatory pathway during postnatal development.Conﬂict of interest statement
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